Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest zinc deficiency Stories

2011-11-08 13:00:00

ANN ARBOR, Mich., Nov. 8, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that George J. Brewer, M.D., the Company's Senior Vice President of Research & Development, will be a featured speaker at the 52nd Annual Meeting of the American College of Nutrition to be held in Morristown, New Jersey, on November 16-19, 2011. Dr. Brewer is the Morton S. and Henrietta Sellner...

2011-11-07 08:00:00

ANN ARBOR, Mich., Nov. 7, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), announced today that it has executed an agreement with F&F Foods of Chicago, Illinois, to provide commercial-scale manufacturing of wellZin(TM), the Company's oral zinc lozenge to reduce the duration and symptoms of the common cold. Adeona is planning to commercialize wellZin, a lozenge that contains 13.3 mg of zinc acetate, based on formulations clinically tested by Ananda S. Prasad, M.D.,...

2011-10-12 07:58:00

ANN ARBOR, Mich., Oct. 12, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that George J. Brewer, M.D., the Company's Senior Vice President of Research & Development, will be a featured speaker at the 2011 International Society for Trace Element Research in Humans Conference to be held in Belek, Turkey, on October 16-21, 2011. Dr. Brewer is the Morton S. and Henrietta...

2011-08-25 07:58:00

ANN ARBOR, Mich., Aug. 25, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN) announced today that it has appointed George A. Eby, a researcher who has conducted multiple clinical studies of zinc lozenges for the common cold, as a member of its Scientific Advisory Board. Mr. Eby is a pioneer in the development of zinc lozenges as a treatment for the common cold. He has devoted more than 30 years to the study of zinc and is the executive director of the George Eby Research...

2011-08-15 07:57:00

ANN ARBOR, Mich., Aug. 15, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, today reported its second quarter 2011 financial results for the period ended June 30, 2011, as well as updates since the beginning of the second quarter. Updates since the beginning of the second quarter include: Drug Development Programs Multiple Sclerosis (MS) As of August 1, 2011, 140 of 150 patients have been...

2011-08-09 08:00:00

ANN ARBOR, Mich., Aug. 9, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that it will hold its 2nd quarter 2011 investor conference call on Monday, August 15, 2011, at 2:00pm EDT. James S. Kuo, M.D., M.B.A., Adeona's Chief Executive Officer, will provide an overview of the Company's drug development programs and commercialization efforts of reaZin(TM) and wellZin(TM). Julie...

2011-07-28 08:00:00

ANN ARBOR, Mich., July 28, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), announced today that it has acquired exclusive access to two sets of clinical data demonstrating, with statistical significance, the safety and efficacy of a particular oral zinc formulation in reducing the duration and severity of symptoms associated with the common cold. The common cold is one of the most widespread illnesses and is a leading cause of visits to the doctor and absenteeism from...

2011-06-02 08:00:00

ANN ARBOR, Mich., June 2, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today positive findings based on further analyses from the clinical study evaluating reaZin along with near-term plans for its Alzheimer's disease program. After reviewing the statistical analysis with the Company's scientific advisors, Adeona intends to conduct another Alzheimer's disease clinical study to...

2011-05-16 16:51:00

ANN ARBOR, Mich., May 16, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, today reported its first quarter 2011 financial results for the three month period ended March 31, 2011, as well as updates since the beginning of the 1st quarter. Updates since the beginning of the 1st quarter include: Clinical Programs Zinc Deficiency Associated with Alzheimer's Disease Clinical results: Top-line...

2011-04-14 19:00:00

ANN ARBOR, Mich., April 14, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today top-line results from its clinical study evaluating reaZin for the dietary management of Alzheimer's disease (AD) and mild cognitive impairment (MCI). The clinical study met the primary outcome of increasing serum zinc and decreasing serum free copper. In addition, secondary outcomes of mental status as...